Understanding the crosstalk between oncogene signaling, ROS production by p66Shc, and transformation may identify novel targets for treating melanoma and possibly help to overcome the development of resistance to mutant BRAF‐specific kinase inhibitors (Luke et al., 2017). Here, BRAF is linked to melanoma.